Table 2. Survival of Secondary LVS Challenge by WT and IL-12Rβ2 KO Mice.
| Mouse strain (C57BL/6J) | Primary LVS dose, Day 0 | Secondary challenge, Day 45 | Number of deaths/total | Mean time to death (days) |
|---|---|---|---|---|
| WT | PBS | 2 × 106 i.p. | 5/5 | 4 |
| WT | 1 × 103 i.d. | 2 × 106 i.p. | 0/5 | n/a |
| IL-12Rβ2 KO | 1 × 103 i.d. | 2 × 106 i.p. | 0/5 | n/a |
| WT | 1 × 101 i.n. | 2 × 106 i.p. | 0/5 | n/a |
| IL-12Rβ2 KO | 1 × 101 i.n. | 2 × 106 i.p. | 0/5 | n/a |
| WT | PBS | 5 × 107 i.n. | 5/5 | 7 |
| WT | 1 × 103 i.d. | 5 × 107 i.n. | 1/5 | 7 |
| IL-12Rβ2 KO | 1 × 103 i.d. | 5 × 107 i.n. | 0/5 | n/a |
| WT | 1 × 101 i.n. | 5 × 107 i.n. | 0/5 | n/a |
| IL-12Rβ2 KO | 1 × 101 i.n. | 5 × 107 i.n. | 0/5 | n/a |
WT and IL-12Rβ2 KO mice were vaccinated with indicated doses i.d. or i.n., followed by i.p. or i.n. secondary challenge. Actual vaccination and challenge doses were confirmed by simultaneous plate count. These data are representative of two independent experiments for i.p. and i.n. challenge. n/a, Not applicable.